Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2022 | The role of clinical trials in improving treatment options for SCD

John James • 4 Apr 2022
BSH 2022
Non-Malignant Sickle Cell Disease

John James, OBE, Sickle Cell Society, London, UK, briefly discusses treatment options for patients with sickle cell disease (SCD) and the role of the Sickle Cell Society in improving these. While there have been no recent developments in new treatments, Mr James highlights the benefit of the increasing number of clinical trials in this field, and their importance in providing SCD patients with improved therapeutic options. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.

More from John James

2:05
An insight into the role of the Sickle Cell Society
John James • 4 Apr 2022
1:22
The APPG report on poor quality care for SCD
John James • 4 Apr 2022

Related Videos

2:38
Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases
Rita Beier • 15 Apr 2024
2:18
A global view of transfusion-dependent thalassemia: standard of care, outcomes, and unmet needs
Ali Taher • 15 Apr 2024
1:24
The future of CAR T-reg cells: organ transplantation & autoimmune disease
Zinaida Good • 9 Apr 2024
1:23
Developing a PRO collection tool for patients with SCD: key themes which are important to patients
Nirmish Shah • 8 Dec 2023
The content of VJHemOnc is intended for healthcare professionals